Peptide receptor radionuclide therapy in the management of neuroendocrine tumors (Neoplasms)*: Fundamentals and salient clinical practice points for medical oncologists

Sandip Basu; Rahul Parghane; Rohit Ranade; Pradeep Thapa; Anant Ramaswamy; Vikas Ostwal; Bhawna Sirohi; Dipanjan Panda; Shailesh V Shrikhande

doi:10.4103/ijmpo.ijmpo_161_19

Users Online: 59

EDITORIAL

Year : 2019 | Volume : 40 | Issue : 2 | Page : 165-171

Peptide receptor radionuclide therapy in the management of neuroendocrine tumors (Neoplasms)*: Fundamentals and salient clinical practice points for medical oncologists

Sandip Basu¹, Rahul Parghane¹, Rohit Ranade¹, Pradeep Thapa¹, Anant Ramaswamy², Vikas Ostwal², Bhawna Sirohi³, Dipanjan Panda⁴, Shailesh V Shrikhande⁵
¹ Radiation Medicine Centre Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe; Homi Bhabha National Institute, DAE's University, Mumbai, Maharashtra, India
² Homi Bhabha National Institute, DAE's University; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
³ Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra; Department of Medical Oncology, Max Institute of Cancer Care, New Delhi, India
⁴ Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India
⁵ Homi Bhabha National Institute, DAE's University; Department of Surgical Oncology, Gastrointestinal and Hepato-Pancreato-Biliary Service, Tata Memorial Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Sandip Basu
Radiation Medicine Centre Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai - 400 012, Maharashtra
India

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/ijmpo.ijmpo_161_19

This editorial commentary is an expert summary of “Peptide Receptor Radionuclide Therapy (PRRT),” encompassing the essential fundamentals and salient clinical practice points, deliberated and designed in a point-wise manner with theme-based subheadings. Emphasis has been laid on the topics of practical relevance to the referring oncologists with relevant finer points where necessary. A part of the presented overview has been generated from the authors' own practical experience of more than 3500 successful therapies delivered over the last 9 years at a large tertiary care PRRT setting by the joint efforts of Radiation Medicine Centre (RMC), Bhabha Atomic Research Centre (BARC), and Gastrointestinal services of Tata Memorial Hospital (TMH) at the TMH-RMC premises. While the technical indigenization is beyond the scope of this treatise, we must mention here that India had been one of the frontrunners in this treatment modality, and the PRRT services in this country were developed purely as an indigenous effort right from the production of the radionuclide (177-Lutetium) at the reactor and radiolabeling and production of the radiopharmaceutical (¹⁷⁷Lu-DOTATATE) by the radiopharmaceutical scientists at the BARC and RMC; such an endeavor allowed this very specialized therapy to be delivered at a very affordable cost in our setting which could be viewed as a major societal contribution of the atomic energy research in this country.

[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	281

Printed	16

Emailed	0

PDF Downloaded	71

Comments	[Add]